Exact Sciences Corporation (NASDAQ: EXAS) is a prominent player in the healthcare sector, focusing on cancer prevention and early detection. The company is known for its innovative products like Cologuard and Oncotype DX, which have gained trust in the medical community. Exact Sciences competes with other diagnostic companies, striving to lead in the field of cancer diagnostics.
On November 4, 2025, Robert W. Baird set a price target of $88 for EXAS, while the stock was priced at $72.07. This suggests a potential increase of about 22.11%. The stock's current price is $70.94, reflecting a 5.91% rise or $3.96. The stock has fluctuated between $67.97 and $72.81 today, with a market cap of $13.43 billion.
Exact Sciences recently reported strong third-quarter results, surpassing expectations. The company achieved earnings of 24 cents per share, outperforming the anticipated loss of 7 cents. Quarterly sales reached $850.7 million, exceeding the forecasted $810.2 million. These results have led the company to raise its full-year 2025 sales guidance to $3.22 billion-$3.235 billion.
Kevin Conroy, the CEO, emphasized the company's dedication to cancer prevention and early detection. He highlighted the success of their patient-centric platform and trusted brands, Cologuard and Oncotype DX. The momentum from these successes is driving growth and advancing new tests like Cancerguard, strengthening their financial performance.
The trading volume for EXAS is 3,962,279 shares on the NASDAQ exchange. Over the past year, the stock has reached a high of $72.83 and a low of $38.81. The company's strong financial performance and innovative products position it well for future growth, as highlighted by the recent price target increase by Robert W. Baird.
